持续性狼疮低疾病活动度状态与系统性红斑狼疮结局改善的关联:一项多国前瞻性队列研究
该多国前瞻性队列纳入3449例系统性红斑狼疮(SLE)患者,中位随访2.8年,评估持续性狼疮低疾病活动度状态(LLDAS)与缓解对不可逆损伤累积和发作的保护关联,发现持续至少3个月的LLDAS或缓解即与损伤累积和发作风险降低相关,且持续时间越长保护越强。
要点
- 持续LLDAS超过3个月与损伤累积风险降低相关(HR 0.60,95%CI 0.51-0.71,p<0.0001)。
- 持续LLDAS超过3个月与发作风险降低相关(HR 0.56,95%CI 0.51-0.63,p<0.0001)。
- 持续LLDAS或缓解时间越长,保护关联越强。
核心结论
- 观察到LLDAS和缓解对损伤累积和发作具有显著保护关联,确立持续3个月LLDAS或缓解作为保护性阈值,并显示持续时间越长保护越强。
研究设计与样本
- 前瞻性、多国、纵向队列研究,2013年5月1日至2020年12月31日随访,纳入18岁及以上SLE患者,来自12个国家25个中心,共3449例,中位随访2.8年(IQR 1.1-5.6),总计37662次访视。
主要发现
- 3180例(92.2%)为女性,3031例(87.9%)为亚洲族裔,2506例(72.7%)至少有一次持续LLDAS。
- 任何持续超过3个月的LLDAS或缓解与损伤累积减少相关(LLDAS:HR 0.60,95%CI 0.51-0.71,p<0.0001;缓解:HR 0.66,95%CI 0.57-0.76,p<0.0001)。
- 任何持续超过3个月的LLDAS或缓解与发作减少相关(LLDAS:HR 0.56,95%CI 0.51-0.63,p<0.0001;缓解:HR 0.66,95%CI 0.60-0.73,p<0.0001)。
- 持续LLDAS持续时间增加对应保护关联增强。
- 持续性DORIS缓解或无激素缓解较LLDAS更难以达到。
关键数值与推荐
- 持续LLDAS或缓解定义为连续两次或以上访视且至少3个月处于相应状态。
- 主要结局为不可逆损伤累积,采用SLICC/ACR损伤指数测量;关键次要结局为发作,采用SELENA发作指数测量。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Validation of protective associations of the lupus low disease activity state (LLDAS) against flare, irreversible damage, health-related quality of life, and mortality has enabled the adoption of treat-to-target strategies in patients with systemic lupus erythematosus (SLE). Previous validation studies were of short duration, limiting the ability to detect longer term signals in flare rate and irreversible damage. In addition, previous studies have focused on percent time at target, rather than actual periods of time that are more useful in clinical practice and trials. We assessed long-term protective associations of LLDAS and remission, and specifically examined protective thresholds of sustained LLDAS and remission. METHODS: Patients aged 18 years or older with SLE were followed up from May 1, 2013, to Dec 31, 2020 in a prospective, multinational, longitudinal cohort study. Patients were recruited from 25 centres in 12 countries. Multi-failure time-to-event analyses were used to assess the effect of sustained LLDAS on irreversible damage accrual (primary outcome; measured with the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index) and flare (key secondary outcome; measured with the SELENA Flare Index), with dose exposure and threshold effects studied. Sustained LLDAS or remission were defined as two or more consecutive visits over at least 3 months in the respective state. This study is registered with ClinicalTrials.gov, NCT03138941. FINDINGS: 3449 patients were followed up for a median of 2·8 years (IQR 1·1-5·6), totalling 37 662 visits. 3180 (92·2%) patients were women, and 3031 (87·9%) were of Asian ethnicity. 2506 (72·7%) patients had sustained LLDAS at least once. Any duration of sustained LLDAS or remission longer than 3 months was associated with reduced damage accrual (LLDAS: hazard ratio 0·60 [95% CI 0·51-0·71], p<0·0001; remission: 0·66 [0·57-0·76], p<0·0001) and flare (LLDAS: 0·56 [0·51-0·63], p<0·0001; remission: 0·66 [0·60-0·73], p<0·0001), and increasing durations of sustained LLDAS corresponded to increased protective associations. Sustained DORIS remission or steroid-free remission were less attainable than LLDAS. INTERPRETATION: We observed significant protective associations of LLDAS and remission against damage accrual and flare, establish a threshold of 3 months sustained LLDAS or remission as protective, and demonstrate deepening protection with longer durations of sustained LLDAS or remission. FUNDING: The Asia Pacific Lupus Collaboration receives project support grants from AstraZeneca, Bristol Myers Squibb, EMD Sereno, GSK, Janssen, Eli Lilly, and UCB.
引用
- Golder V, Kandane-Rathnayake R, Li N, et al. Association of sustained lupus low disease activity state with improved outcomes in systemic lupus erythematosus: a multinational prospective cohort study. Lancet Rheumatol. 2024. PMID: 38876129. doi:10.1016/S2665-9913(24)00121-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。